Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease

Via Peters

NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) — Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, announces today they will be pursuing the 505(b)(2) pathway for its investigational agent, H-100™, a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, a condition impacting more […]